Thrombophilia and adverse pregnancy outcome

Croatian Medical Journal

Volumn 42, Issue 2, 2001, Pages 135-145

  Mousa, H A ^a   Alfirevic Z ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Activated protein C resistance; Antiphospholipid syndrome; Antithrombin III; Factor V; Hematologic; Hyperhomocysteinemia; Pregnancy complications; Protein C deficiency; Protein S deficiency; Prothrombin; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III DEFICIENCY; DISEASE PREDISPOSITION; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; PREGNANCY COMPLICATION; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA;

FEMALE; FETAL DEATH; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOPHILIA;

EID: 0035021560     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
2. The challenge of thrombophilia in maternal-fetal medicine
3. Inherited thrombophilia and pregnancy
4. Thrombophilia: A mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in placenta
5. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review
6. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia
7. Elevated circulating homocyst(e)ine levels in placental vascular disease and associated preelampsia
8. Severe preeclampsia associated with co-inheritance of factor V Leiden mutation and protein S deficiency
9. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy
10. Hyperhomocysteinemia: A risk factor for placental abruption or infarction
11. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy
12. Activated protein C resistance and factor V Leiden mutation can be associated with first as well as second trimester recurrent pregnancy loss
13. Hyperhomocysteinemia and protein S deficiency in-complicated pregnancies
14. Case-control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic antecedent
15. Thrombophilia-associated pregnancy wastage
16. Antiphospholipid syndrome and pregnancy loss
17. Pregnancy complications in women with recurrent miscarriages associated with antiphospholipid antibodies treated with low dose aspirin and heparin
18. Increased frequency of genetic thrombophilia in women with complications of pregnancy
19. Inherited hypercoagulable states
20. Guidelines for the management of thrombophilia
21. Inherited thrombophilia: Part 1
22. Inherited thrombophilia: Part 2
23. Thrombophilia as a multigenic disease
24. Increased fetal loss in women with heritable thrombophilia
25. Underlying disorders associated with severe early-onset preeclampsia
26. Prevalence of protein C deficiency in the healthy population
27. Inherited thrombophilia: Pathogenesis, clinical syndromes and management
28. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes
29. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease
30. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women
31. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
32. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
33. Activated protein C resistance: Clinical implications
34. Mutation in blood coagulation factor V associated with resistance to activated protein C
35. Association of idiopathic venous thromboembolism with single point-mutation at Arg 506 of factor V
36. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
37. World distribution of factor V Leiden
38. Venous thrombosis: A multicausal disease
39. Second trimester pregnancy loss is associated with activated protein C resistance
40. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses
41. First trimester repeated abortion is not associated with activated protein C resistance
42. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction
43. The factor V Leiden mutation is not a common cause of recurrent miscarriage
44. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss
45. Thrombophilia polymorphisms are common in women with fetal loss without apparent cause
46. Factor V Leiden and prothrombin G 20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages
47. Thrombosis in pregnancy: Maternal and fetal issues
48. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women
49. The factor V Leiden mutation may predispose women to severe preeclampsia
50. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome
51. HELLP syndrome associated with factor V R506Q mutation
52. Resistance to activated protein C and the Leiden mutation: High prevalence in patients with abruptio placentae
53. Factor V Leiden mutation an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis
54. Activated protein C resistance a major risk factor for thrombosis
55. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
56. Activated protein C resistance and the FV: R506Q mutation in a random population sample associations with cardiovascular risk factors and coagulation variables
57. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure
58. Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation
59. Acquired activated protein C resistance in pregnancy and association with increased thrombin generation and fetal weight
60. Effects of vitamin B12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentration
61. Heritable coagulopathies in pregnancy
62. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations
63. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians
64. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylene-tetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease
65. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
66. Genetic risk factor for unexplained recurrent early pregnancy loss
67. Methylene tetrahydrofolate reductase 677 C→T mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss
68. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
69. Increased risk for venous thrombosis in carriers of the prothrombin G (A20210 gene variant)
70. Normal prevalence of the G20210A prothrombin gene mutation in women with recurrent miscarriage
71. Prothrombin 20210 G-A mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss
72. Syndrome of the black swan
73. Antiphospholipid antibody
74. The prevalence and biological significance of lupus anticoagulant and anticardiolipin antibodies in general obstetric population
75. Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations
76. Antiphospholipid antibodies and beta-2-glycoprotein-I in 500 women with recurrent miscarriage: Results of a comprehensive screening approach
77. Antiphospholipid antibodies in pregnancy
78. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies
79. Inter-laboratory variation in antiphospholipid antibody testing
80. Antiphospholipid antibodies and thrombosis
81. The development of antiphospholipid antibodies in hemophilia is linked to infection with hepatitis C
82. HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA)
83. Antiphospholipid antibodies directed not to cardiolipin but to a plasma protein cofactor
84. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H)
85. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
86. Beta 2-glycoprotein I-dependent and -independent anticardiolipin antibodies in healthy pregnant women
87. Beta 2-glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women
88. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid: Importance of antigen density and bivalent binding
89. Beta 2-glycoprotein I (beta 2-GPI) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies
90. Antiphospholipid antibodies in obstetrics: New complexities and sites of action
91. Anti-beta 2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome
92. Beta 2-glycoprotein I as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss
93. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages
94. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss: A case-control study
95. Antiphospholipid antibodies and fetal death
96. Lack of association between antiphospholipid antibodies and first trimester spontaneous abortion: Prospective study of pregnancies detected within 21 days of conception
97. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies
98. Antiphospholipid antibodies proposed mechanisms of action
99. Antibody to cardiolipin, lupus anticoagulant and fetal death
100. Pregnancy loss in the antiphospholipid syndrome
101. Acquired thrombophilia in pregnancy
102. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies
103. Anntiphospholipid antibodies in patients with preeclampsia
104. Can maternal antiphospholipid antibodies predict the birth of a small-for-gestational age child?
105. Anticardiolipin antibodies in preeclampsia and intrauterine growth restriction
106. Antiphospholipid antibodies and reproduction: The antiphospholipid antibody syndrome
107. Absence of thrombosis in subjects with heterozygous protein C deficiency
108. Prevalence of antithrombin deficiency in the healthy population
109. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage with phospholipid antibodies (or antiphospholipid antibodies)
110. Intrauterine death due to umbilical cord thrombosis secondary to antiphospholipid syndrome
111. Thrombophilias: Diagnosis and treatment of thrombophilia relating to contraception and pregnancy
112. Congenital thrombophilia
113. Inherited coagulation disorders and thrombophilia and pregnancy
114. Perinatal aspects of inherited thrombophilia
115. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: Study of 78 women
116. Management of pregnancy in women with antithrombin III congenital defect: Report of four cases
117. Epidemiology, risk factors, and prophylaxis of venous thromboembolism in obstetrics and gynaecology
118. Treatment of venous thrmboembolism
119. Effects of folic acid and vitamin B6 Supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction
120. The effect of folic acid fortification on plasma folate and total homocysteine concentrations
121. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin alone
122. Deep vein thrombosis during pregnancy and the puerperium: A meta analysis the period of risk and the leg of presentation
123. The placenta in maternal hyperhomocysteinemia
124. Do Placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?